Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma

Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Ther Oncolytics
Hlavní autoři: Federico, Aniello, Steinfass, Tamara, Larribère, Lionel, Novak, Daniel, Morís, Francisco, Núñez, Luz-Elena, Umansky, Viktor, Utikal, Jochen
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Gene & Cell Therapy 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327877/
https://ncbi.nlm.nih.gov/pubmed/32637583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.06.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky